【Cochrane简语概要】口服黄芪能否预防儿童急性呼吸道感染？

（图片来源于网络）

综述问题 

我们评价了单独使用口服黄芪预防14岁以下儿童急性呼吸道感染（acute respiratory infections, ARTIs）频繁发作的益处和危害的证据，并与安慰治疗进行了比较。ARTIs包括感冒、喉咙痛、喉炎、流感、支气管炎和肺炎。

研究背景 

许多疗法被用于预防ARTIs，尤其是儿童。黄芪是一种广泛使用和可用的草药疗法，已经在中国使用了数千年，以帮助预防ARTIs。人们认为它可以提高免疫力。近五分之一的儿童经常接受ARTIs治疗，占儿童处方抗生素的75%。由于大多数ARTIs是由病毒引起的，抗生素在治疗这些疾病时并不有效。

检索日期 

我们检索了截止到2015年12月31日为止的文献资料。

研究特征 

我们确定了6080个可能相关的记录。在删除重复记录和那些不符合我们纳入标准的记录后，我们获得了120个全文研究。我们仔细评价了这些研究，以便可能纳入。我们排除了大多数研究，因为它们的诊断标准不明确、采用黄芪制剂与其他制剂配伍、或者黄芪没有与安慰治疗进行比较。没有研究符合我们的纳入标准，所以我们无法分析任何结果。

研究经费来源 

我们无法评估研究资金来源。

主要结局 

我们没有发现任何将单独口服黄芪与安慰治疗相比较来预防14岁以下儿童的ARTI频繁发作的研究。还需要精心设计的研究来调查这个问题，以便在未来进行评估。

证据质量 

我们无法评估证据的质量。

结论: 

我们发现没有足够的证据来确定口服黄芪作为预防14岁以下儿童频繁发生ARTIs的唯一干预措施的有效性和安全性。

【Cochrane Plain Language Summary】Can oral Astragalus (Huang qi) prevent frequent acute respiratory tract infections in children?

Review question 

We assessed evidence for the benefits and harms of oral Astragalus used alone to prevent frequent episodes of acute respiratory infections (ARTIs) in children aged up to 14 years, compared to a dummy treatment. ARTIs include colds, sore throats, laryngitis, influenza, bronchitis and pneumonia.

Background 

Many therapies are used to prevent ARTIs, especially in children. Astragalus, is a widely used and available herbal therapy that has been used for thousands of years in China to help prevent ARTIs. It is thought to boost immunity. Almost one in five children experience frequent ARTIs and treatment accounts for up to 75% of all prescribed antibiotics for children. Because most ARTIs are caused by viruses, antibiotics are not effective in treating these illnesses.

Search date 

We searched the literature up to 31 December 2015.

Study characteristics 

We identified 6080 potentially relevant records. After removing duplicate records, and those that did not meet our inclusion criteria, we obtained 120 full-text studies. We carefully assessed these studies for possible inclusion. We excluded most studies because: they presented unclear diagnosis criteria; Astragalus preparation was used with other agents; or Astragalus was not compared with a dummy treatment. No studies met our inclusion criteria and so we were unable to analyse any results.

Study funding sources 

We could not assess study funding sources.

Key results 

We did not find any studies that compared use of oral Astragalus alone with a dummy treatment to prevent frequent episodes of ARTI in children aged up to 14 years. Well-designed, conducted and reported studies investigating this issue are needed to enable assessment in the future.

Quality of the evidence 

We could not assess evidence quality.

Authors' conclusions: 

We found insufficient evidence to enable assessment of the effectiveness and safety of oral Astragalus as a sole intervention to prevent frequent ARTIs in children aged up to 14 years.

译者：刘雪寒；审校：鲁春丽；编辑排版：张晓雯，北京中医药大学循证医学中心

想要报名成为Cochrane翻译志愿者，查看更多内容，请关注公众号了解详情！

中医循证医学摇篮，传播循证理念方法，彰显中医优势特色，促进中医药国际化。

长按识别二维码，关注我们

点击“阅读原文”，查看中英文完整摘要。